CompletedNot Applicable

Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients

United States267 participantsStarted 2020-03-01

Plain-language summary

This study explored the incidence of morbidity and mortality associated with AKI in critically ill adult patients infected with COVID-19. There are two groups for comparison. Group1. patients were directly admitted to the intensive care unit (ICU) from the emergency department (ED) Group 2. patients were initially managed on the medical floor and later transferred to the ICU for worsening respiratory status. The investigating team evaluated the correlation of inflammatory markers and common risk factors such as obesity, diabetes, hypertension and ethnicity to the development of AKI in the target population. The primary outcome is mortality participants will received their regular healthcare in a medical setting

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: positive for SARS-CoV-2 on a real-time polymerase chain reaction test (RT-PCR) upon admission to the hospital Exclusion Criteria: chronic kidney disease end stage renal disease

What they're measuring

Mortality

Timeframe: from admission until death from any cause, whichever comes first, assessed up to three months

Trial details

NCT IDNCT05964088

SponsorArrowhead Regional Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-02-12

View on ClinicalTrials.gov More Acute Kidney Injury trials